Literature DB >> 6787156

Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins.

E J Schaefer, D W Anderson, L A Zech, F T Lindgren, T B Bronzert, E A Rubalcaba, H B Brewer.   

Abstract

The metabolism of apolipoproteins A-I and A-II, as well as other high density lipoprotein (HDL) constituents, was studied in patients with homozygous familial HDL deficiency (Tangier disease) prior to and after plasma exchange or HDL infusion. Mean plasma apoA-I, apoA-II, and HDL cholesterol values in homozygotes (n = 2) were 2.0 mg/dl, 2.7 mg/dl, and 1.5 mg/dl, respectively, and in a normal control subject were 125.1 mg/dl, 23.0 mg/dl, and 53.0 mg/dl, respectively. Based on radioiodinated apoA-I and apoA-II kinetic studies in the baseline state, synthesis rates for apoA-I and apoA-II in mg/kg/day were 3.81 and 1.61, respectively, in one homozygote (patient B) and 11.82 and 1.99, respectively, in the normal subject. ApoA-I and apoA-II plasma residence times in days were 0.22 and 0.81, respectively, in the homozygote, and 4.04 and 4.44, respectively, in the normal subject. These data indicate that this homozygote had both a moderate decrease in the synthetic rates of apoA-I and apoA-II, as well as a marked decrease in the plasma residence times of these two apolipoproteins. In one homozygote (patient A) following a complete plasma exchange during cardiopulmonary bypass, plasma HDL cholesterol, apoA-I, and apoA-II levels were very similar to pre-exchange values within 64 hr after exchange. A second homozygote (patient B) received HDL intravenously as well as 125I-labeled apoA-I and 131I-labeled apoA-II. Following infusion, the residence time in days for HDL subfractions, HDL2b, HDL2a, and HDL3 were 0.1, 0.8, and 2.7, respectively. HDL protein and phospholipid both had a monoexponential decay, with residence times of 0.7 days, while HDL triglyceride disappeared monoexponentially with a residence time of 0.5 days. HDL cholesterol had a biexponential decay, with the residence time of the slow component being 0.7 days. Plasma and HDL apoA-I decayed down to baseline values significantly faster than did plasma and HDL apoA-II. ApoA-II specific radioactivity decreased throughout the course of the infusion study in both plasma and HDL, while apoA-I specific radioactivity decreased slightly, then rose, and subsequently declined in both plasma and HDL. The data indicate that the rapid and altered catabolism of apoA-I and apoA-II in Tangier homozygotes persists despite major increases in the plasma pool size of these proteins. In addition, following HDL infusion, HDL2b and HDL2a disappeared at a faster rate than HDL3, HDL cholesterol and triglyceride were catabolized at a faster rate than HDL protein and phospholipid, and apoA-I disappeared more rapidly than apoA-II. These observations may have important implications with regard to the catabolism of HDL subfractions and constituents in normal man.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6787156

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  11 in total

1.  Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred.

Authors:  A T Remaley; S Rust; M Rosier; C Knapper; L Naudin; C Broccardo; K M Peterson; C Koch; I Arnould; C Prades; N Duverger; H Funke; G Assman; M Dinger; M Dean; G Chimini; S Santamarina-Fojo; D S Fredrickson; P Denefle; H B Brewer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I.

Authors:  Jenelle M Timmins; Ji-Young Lee; Elena Boudyguina; Kimberly D Kluckman; Liam R Brunham; Anny Mulya; Abraham K Gebre; Jonathan M Coutinho; Perry L Colvin; Thomas L Smith; Michael R Hayden; Nobuyo Maeda; John S Parks
Journal:  J Clin Invest       Date:  2005-04-07       Impact factor: 14.808

3.  ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice.

Authors:  B L Vaisman; G Lambert; M Amar; C Joyce; T Ito; R D Shamburek; W J Cain; J Fruchart-Najib; E D Neufeld; A T Remaley; H B Brewer; S Santamarina-Fojo
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

4.  Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.

Authors:  Suzanne E Wahrle; Hong Jiang; Maia Parsadanian; Jungsu Kim; Aimin Li; Amanda Knoten; Sanjay Jain; Veronica Hirsch-Reinshagen; Cheryl L Wellington; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

5.  Elevated complement activities of sera from patients with high density lipoprotein deficiency (Tangier disease): the presence of normal level of clusterin and the possible implication in the atherosclerosis.

Authors:  N H Choi-Miura; T Sakamoto; S Ohtaki; H Nakamura; S Ishizawa; Y Takagi; K Gomi; M Tomita
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

6.  Genetic and secondary causes of severe HDL deficiency and cardiovascular disease.

Authors:  Andrew S Geller; Eliana Y Polisecki; Margaret R Diffenderfer; Bela F Asztalos; Sotirios K Karathanasis; Robert A Hegele; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2018-10-17       Impact factor: 5.922

7.  Tangier disease: a structural defect in apolipoprotein A-I (apoA-I Tangier).

Authors:  L L Kay; R Ronan; E J Schaefer; H B Brewer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

8.  Tangier disease. High density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-i (ApoA-ITangier).

Authors:  E J Schaefer; L L Kay; L A Zech; H B Brewer
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

9.  Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling.

Authors:  Jacob M Basak; Jungsu Kim; Yuriy Pyatkivskyy; Kristin R Wildsmith; Hong Jiang; Maia Parsadanian; Bruce W Patterson; Randall J Bateman; David M Holtzman
Journal:  Mol Neurodegener       Date:  2012-04-18       Impact factor: 14.195

10.  An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway.

Authors:  James Lu; Katrin Hübner; M Nazeem Nanjee; Eliot A Brinton; Norman A Mazer
Journal:  PLoS Comput Biol       Date:  2014-03-13       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.